GlassScriptPhysician profile
Laura Craig
NPI 1831876440
$2,646.05
in general payments reported to CMS, 2019-2025
25 companies · $1,486 in 2025
The $1,486 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $387 · 2024: $774 · 2025: $1,486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,546 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,546.06 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $728.98 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $244.85 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $243.41 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $151.38 | 2023-2025 | |
| Vanda Pharmaceuticals INC. | $146.78 | 2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $143.34 | 2024-2025 | Caplyta |
| Exact Sciences Corporation | $116.84 | 2023-2025 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $99.99 | 2025 | Enhertu |
| Lilly USA, LLC | $97.98 | 2024-2025 | Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $96.08 | 2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $83.91 | 2023-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.53 | 2024-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $65.04 | 2024-2025 | Rexulti |
| Glaxosmithkline, LLC. | $63.09 | 2023-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Axsome Therapeutics, INC. | $42.38 | 2023-2025 | Auvelity |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $41.58 | 2025 | Inspire |
| Sumitomo Pharma America, INC. | $34.50 | 2025 | Gemtesa |
| Currax Pharmaceuticals LLC | $30.31 | 2023 | Contrave |
| Medtronic, INC. | $27.70 | 2024 | Intellis Adaptivestim |
| Abbott Laboratories | $22.03 | 2025 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $21.47 | 2024 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $20.92 | 2023 | |
| Astellas Pharma US INC | $19.58 | 2024 | Veozah |
| Lundbeck LLC | $18.62 | 2025 | Rexulti |
| Tempus Ai, INC | $13.76 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Craig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.